KalVista Pharmaceuticals Inc (NAS:KALV)
$ 12.11 0.25 (2.11%) Market Cap: 510.90 Mil Enterprise Value: 431.79 Mil PE Ratio: 0 PB Ratio: 4.73 GF Score: 30/100

Kalvista Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 27, 2021 / 12:40PM GMT
Release Date Price: $18.9 (+1.89%)
Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Senior Analyst

Hello. Good morning, and welcome to the Cantor Global Healthcare Conference for 2021. My name is Charles Duncan. I'm a Managing Director and Senior Biotechnology Analyst with the firm's Equity Research Department. And this is day 1 of the Cantor Conference. And I have to say, what a year it has been since we last hosted our clients in the fall of 2020.

So it's a pleasure to introduce the next -- actually, the first presenting speaker for me. This is KalVista Pharmaceuticals. KalVista is an interesting platform-enabled drug developer, and I -- it's a pleasure to introduce the company's CEO, Dr. Andrew Crockett. I also have Mr. Ben Palleiko, the company's CFO and CBO with me today; and Dr. Chris Yea, the company's Chief Development Officer. Gentlemen, good morning. How are you?

Thomas Andrew Crockett;Christopher M. Yea
KalVista Pharmaceuticals, Inc. - CEO & Director;KalVista Pharmaceuticals, Inc. -

Chaz, thanks for having us today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot